Abstract: A chip holding tool (12) comprises: a holding surface (24) for holding a semiconductor chip (100) in a non-contact manner; a suction path (33) for providing negative pressure at the holding surface (24) and drawing the semiconductor chip (100) by suction; and an ultrasonic generator (14) for providing ultrasonic oscillation to the holding surface (24), wherein the size of the outer shape of the holding surface (24) is larger than the size of the outer shape of the semiconductor chip (100). A positioning groove (36) having a shape conforming to at least a portion of the outer shape of the semiconductor chip (100) is formed in the holding surface (24).

Abstract: Disclosed is a compound capable of inhibiting interleukin 17A (IL-17A), which is represented by formula (I). An application of the compound or a stereoisomer thereof in the preparation of drugs for inhibiting IL-17A is also provided.

Abstract: A compound of formula (I): where X1 is C or N, X2 and X3 are independently O, N, NRX or CRX, X4 and X5 are independently C or N, L is —C2-6 alkylene or —C2-6 alkenylene, Z is C(O), S(O) or S(O)2, and Y1, Y2 and Y3 are each independently N or CRY. This application further provides an application of the compound of formula (I) or a stereoisomer thereof in the preparation of a drug for treating a IL-17A-related disease.

Abstract: The present invention discloses a differentially private computation method based on a shuffle model, belonging to the field of data security and personal information protection. The method comprises: constructing a personalized shuffle model; optimizing the data randomization performance of the personalized shuffle model by using a randomization mechanism optimized for non-statistical tasks to obtain an improved personalized shuffle model; and using the improved personalized shuffle model to perform encryption and decryption on user input data. The invention enables personalized outputs while maintaining privacy and benefiting from the privacy amplification effect of the shuffle model. Through an innovative combination of encryption and anonymization, the invention addresses the long-standing challenges of privacy protection in non-statistical tasks and demonstrates broad applicability.

Abstract: The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA 5 molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.

Abstract: Provided is an anti-PD-L1 antigen binding protein, capable of binding to primate-derived PD-L1 with a KD value of 1×10?8 M or less. The antigen binding protein can block the binding of PD-1 and CD80 to PD-L1, stimulate the secretion of cytokines in immune cells, and can inhibit tumor growth and/or tumor cell proliferation. Also provided is a fusion protein, comprising human TGFBRII or a fragment thereof and the antigen binding protein. Also provided is an application of the antigen binding protein and/or the fusion protein in the prevention and treatment of tumors or cancers.

Abstract: Provided herein are small interfering ribonucleic acid (siRNA) agents targeting a microtubule-associated protein tau (MAPT) gene and compositions comprising such siRNA agents.

Abstract: A sample analysis system, method and a cell image analysis device. The sample analysis system includes a blood cell analyzer, a smear preparation apparatus, a cell image analysis apparatus, and a controller. The controller obtains a test result of at least one sample from the blood cell analyzer. When one sample needs to be analyzed by the cell image analysis device, the controller can further control an imaging condition used by the cell image analysis device according to a value of at least one type of cells in the test result of the sample, such that the cell image analysis device can automatically selects an imaging condition matching the test result for imaging according to different test results of the sample. Therefore, a matching imaging condition is used to specifically capture and analyze cell images of a smear of the sample, thereby improving processing efficiency and accuracy.

Abstract: A method and device for the detection of short to ground circuits is disclosed. The method includes (i) connecting to a detection current source that is linked to the high-side lead terminal of the two lead terminals of an electronic control circuit, (ii) disconnecting the low-side switch of the ground terminal of the electronic control circuit, (iii) measuring the voltage of the two lead terminals of the electronic control circuit separately, and (iv) determining whether the high-side lead terminal or the low-side lead terminal of the two lead terminals has a short to ground circuit by comparing the voltages of the two lead terminals. When the voltage of the high-side lead terminal is greater than the voltage of the low-side lead terminal, it is determined that the low-side lead terminal has a short to ground circuit. When the voltage of the high-side lead terminal is equal to the voltage of the low-side lead terminal, it is determined that the high-side lead terminal has a short to ground circuit.

Abstract: The present invention provides a compound as shown in formula I, having a binding effect with E3 ligase protein CRBN, and a use of the compound in the preparation of a medicine for treating abnormal cell proliferation diseases.

Abstract: A process for preparing a zeolite having a CHA-type framework structure comprising X2O3 and YO2, wherein X is a trivalent element and Y is a tetravalent element, which includes (1) preparing a synthesis mixture comprising (A) a source for X2O3, (B) a source for YO2, and (C) a source for an organic structure directing agent (OSDA) comprising a diquaternary ammonium cation of formula (I) or a combination of diquaternary ammonium cations of formula (R1R2R3)N+(CH2)nN+(R4R5R6) (I) as defined in claims and (2) subjecting the synthesis mixture to crystallization conditions to form a zeolite having a CHA-type framework structure. The present invention also relates to the zeolite having a CHA-type framework structure obtained from the process and use of the zeolite in catalysts for selective catalytic reduction of nitrogen oxides.

Abstract: An alignment method for a first semiconductor chip (221) and a second semiconductor chip (231) to be stacked, wherein the first semiconductor chip (221) is ultrasonically vibrated, a lower surface (231a) of the second semiconductor chip (231) is brought close to an upper surface (221a) of the first semiconductor chip (221) so as to overlap the first semiconductor chip (221) that is vibrating ultrasonically and the second semiconductor chip (231) is released to self-align the second semiconductor chip (231) on the first semiconductor chip (221).

Abstract: A fog dissipation device includes a first flow path and a second flow path which are stacked to exchange heat between a first air flow and a second air flow flowing from bottom to top; a first outflow port through which the first air flow flowing out of the first flow path is discharged to the upper side of the fog dissipation device; and a second outflow port through which the second air flow flowing out of the second flow path is discharged to the upper side of the fog dissipation device, wherein the first outflow port and the second outflow port are alternately stacked. The fog dissipation device can play a role in water-saving fog dissipation.

Abstract: The present invention discloses the application of O6-Methyl-2-deoxyguanosine-5-triphosphate (O6-Methyl-dGTP) in the preparation of drugs for the prevention, treatment and/or control of tumours. O6-Methyl-dGTP significantly inhibits tumour proliferation and promotes apoptosis, providing a novel drug candidate for tumour prevention and treatment. Animal experiments confirmed its inhibitory effect on tumours, showing strong industrial applicability as well as significant commercial and social value.

Abstract: Disclosed herein are compounds capable of modulating GPR17 and pharmaceutical compositions of such compounds and methods of treatment for conditions, e.g., neurodegenerative diseases or demyelinating diseases, using such pharmaceutical compositions.

Abstract: A universal contact center service access point is mapped to a service access point specific to a determined modality to establish a connection between a user device and a contact center operator device and associated with that modality. A request for a contact center engagement is obtained from a user device, in which the request includes a universal contact center service access point. Responsive to the request, the universal contact center service access point is mapped, based on a record associating multiple modalities with the universal contact center service access point, to a service access point specific to one of those multiple modalities determined based on information associated with the user device. The contact center engagement is then facilitated over a connection, established based on the mapping, between the user device and a contact center operator device associated with the service access point.

Abstract: A cardiac-targeting extracellular vesicle (EV), an EV for treating cardiovascular disease, and method of preparation and use thereof are provided. The EV contains a fusion sequence of Lamp-2b and peptide targeting cardiacmyocytes, CMP. It has been discovered that the cardiac-targeting EV exhibits the ability to specifically target the heart, thereby serving as a novel delivery tool system for cardiac-targeting therapy. The cardiac-targeting EV is loaded with miR-30d to obtain an EV for treating the cardiovascular disease, which demonstrates significant therapeutic effects on conditions such as cardiac ischemia-reperfusion injury and myocardial hypertrophy. This provides a new therapeutic approach for the clinical treatment of cardiovascular diseases. Additionally, targeted delivery of therapeutic agents using the cardiac-targeting EV is achieved, enabling effective prevention and treatment of cardiac diseases.